SLC5A2 and metabolic dysfunction-associated steatotic liver disease: SGLT2 inhibitors have provided some therapeutic benefits for NAFLD (Aso et al., 2019[8]; Chiang et al., 2020[18]; Ala, 2021[3]; Wei et al., 2021[90]).